Currency In USD
| Previous Close | 1.34 |
| Open | 1.34 |
| Day High | 1.36 |
| Day Low | 1.29 |
| 52-Week High | 2.01 |
| 52-Week Low | 1.04 |
| Volume | 12.81M |
| Average Volume | 15.89M |
| Market Cap | 866.05M |
| PE | -15 |
| EPS | -0.09 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 1.39 |
| Change | 0.01 |
Geron Plans to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
GlobeNewswire Inc.
Feb 11, 2026 12:27 PM GMT
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth qua
Geron Corporation Provides 2026 Financial Guidance
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward buildi